ArticleCell biochemistry and biophysics2025
Bioisosteric and Virtual Screening Approach to Identify Natural Inhibitors of Chikunguya alphavirus nsP3.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chikungunya fever is an arboviral disease characterized by high fever, rash, and intense polyarthralgia, which may persist and evolve into a chronic condition, significantly impairing quality of life. The etiological agent, Chikungunya virus (CHIKV), is an alphavirus transmitted by Aedes aegypti mosquitoes and represents an increasing global public health concern due to its epidemic potential, economic burden, and the lack of specific antiviral therapies. In this context, in silico methodologies have become valuable tools in drug discovery and repurposing. This study aimed to predict natural compounds capable of inhibiting CHIKV non-structural protein 3 (nsP3). A total of 84,215 natural compounds from the ZINC20 database were screened through molecular docking using AutoDock Vina, with nsP3 as the target receptor. Ligand-protein interactions were visualized and analyzed with LigPlot+ and PyMOL. The top candidates were further refined through bioisosteric modifications using MolOpt, and their pharmacokinetic properties were predicted via the pkCSM platform. Among the optimized molecules, three bioisosteres, Chikv_bio1, Chikv_bio2, and Chikv_bio3, demonstrated favorable docking scores, interaction profiles, and ADMET properties, suggesting promising inhibitory activity against nsP3. These findings support the potential of natural compound-based drug design and highlight the importance of advancing to in vitro and in vivo validation to confirm the therapeutic relevance of these candidates and contribute to the development of specific treatments for Chikungunya fever.
Indexed as
Identifiers
40856973What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.